Cynata Therapeutics (STU:51S) Cash Payments : €-7.86 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cynata Therapeutics Cash Payments?

Cynata Therapeutics's Cash Payments for the six months ended in Dec. 2023 was €-1.18 Mil.

Cynata Therapeutics's Cash Payments for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.86 Mil.

Cynata Therapeutics Cash Payments Historical Data

The historical data trend for Cynata Therapeutics's Cash Payments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics Cash Payments Chart

Cynata Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Cash Payments

Get a 7-Day Free Trial

-6.29

-4.34

-7.26

-10.05

-7.86

Cynata Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash Payments	Get a 7-Day Free Trial															-5.91	-2.24	-7.87	-1.18	-6.67

Cynata Therapeutics Cash Payments Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Payments represents cash flow paid from operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Payments" section for non-financial companies:
Payments to Suppliers for Goods and Services
Payments on Behalf of Employees
Other Cash Payments from Operating Activities

Cash Payments for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-7.86 Mil.

Cynata Therapeutics Cash Payments Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's Cash Payments provided by GuruFocus.com. Please click on the following links to see related term pages.

Cynata Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (STU:51S) » Definitions » Cash Payments

Comparable Companies

Traded in Other Exchanges

CYP:Australia

Address

100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121

Website

https://www.cynata.com

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics Headlines

No Headlines